Should you buy Danaher stock now?
Yes, the technical signal for Danaher is currently BUY. Danaher trades at $224.49 as of 9/26/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 4.241 with rising momentum (signal: 2.634); RSI is at 68.9 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $230.83 points to 2.8% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Danaher stock?
The average analyst price target for Danaher is $230.83. The current price is $224.49, which gives an upside of 2.8%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $207.75 and $253.91.
Is Danaher a dividend stock?
Yes, Danaher is a dividend stock with a dividend yield of 0.65%. The payout ratio is 18.7%, which is considered sustainable. The next dividend payment is scheduled for 10/30/2026.
What is the risk of Danaher stock?
Danaher is rated as a stock in the risk category Balanced. the annual standard deviation is 28.5%, which classifies the stock as Balanced.
Is Danaher overvalued?
Danaher is considered fairly valued – the price is close to the analyst price target. Danaher has the following valuation ratios: a P/E ratio of 39.5 (highly valued), a P/S ratio of 6.3, a P/B ratio of 3.0. The stock trades close to the analyst price target and is considered fairly valued.
Is Danaher overbought?
No, Danaher is not overbought. RSI is at 68.9 (neutral zone). The technical indicators show: RSI is at 68.9 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 6.2% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Danaher earnings report?
The date of the next earnings report for Danaher has not been published yet. Check the company's investor calendar for updates.
Is Danaher shorted?
Yes, Danaher is shorted with 1.3% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Danaher stock?
No, insiders are not buying Danaher shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 4 sales. On a net basis, 3,816,649 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 12,026,157 $ sold. Active sellers include Blair Rainer, Zerhouni Elias A., FILLER LINDA and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Danaher a good stock?
Based on our total score, Danaher is rated as a mediocre stock with a total score of 47 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 32/100, Quality: 61/100. In addition: a dividend of 0.65%; technical signal: Strong Buy. Whether Danaher is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Danaher stock?
The outlook for Danaher based on current data: the average analyst price target is $230.83 (+2.8%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 39.5 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Danaher stock rising?
Danaher is rising right now. The technical indicators show: the price is 6.2% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Danaher go?
The average analyst price target for Danaher is $230.83, which corresponds to a potential gain of 2.8% from the current price of $224.49. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Danaher fall?
We lack enough history to give a specific floor for Danaher. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Danaher do?
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology... The company belongs to the Healthcare sector, more specifically the Diagnostics & Research industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Danaher as an investment.
Did Danaher raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Danaher. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Danaher making money or losing money?
Yes, Danaher is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 16.0% — which is solid. The operating margin (profit before interest and taxes) is 19.8%. At a P/E ratio of 39.5, you currently pay 39.5 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Danaher go bankrupt?
The bankruptcy risk of Danaher is rated as low. Altman Z2 (a model for assessing financial distress) is 3.83 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 57% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Danaher have a lot of debt?
No, Danaher has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 57%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Danaher service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 11.1x, and net debt equals 2.8 years of earnings (EBITDA).